Jazz Pharmaceuticals’ zanidatamab shows promising results in HER2-positive biliary tract cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released pivotal new data from its Phase 2b HERIZON-BTC-01 clinical trial assessing zanidatamab in previously treated HER2-positive biliary tract cancer (BTC). The study’s findings were prominently featured at the American Society of Clinical Oncology (ASCO) Annual Meeting today, highlighting significant improvements in overall survival rates and continued positive responses […]